Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Xenetic Biosciences (XBIO) FCF Margin (2023 - 2025)

Xenetic Biosciences' FCF Margin history spans 7 years, with the latest figure at 31.67% for Q4 2025.

  • For Q4 2025, FCF Margin rose 7221.0% year-over-year to 31.67%; the TTM value through Dec 2025 reached 76.83%, up 3586.0%, while the annual FY2025 figure was 76.83%, 3586.0% up from the prior year.
  • FCF Margin reached 31.67% in Q4 2025 per XBIO's latest filing, up from 64.1% in the prior quarter.
  • In the past five years, FCF Margin ranged from a high of 31.67% in Q4 2025 to a low of 226.96% in Q1 2024.
  • Average FCF Margin over 3 years is 121.49%, with a median of 110.95% recorded in 2023.
  • The largest YoY upside for FCF Margin was 12266bps in 2024 against a maximum downside of -4499bps in 2024.
  • A 3-year view of FCF Margin shows it stood at 118.02% in 2023, then increased by 12bps to 103.88% in 2024, then soared by 70bps to 31.67% in 2025.
  • Per Business Quant, the three most recent readings for XBIO's FCF Margin are 31.67% (Q4 2025), 64.1% (Q3 2025), and 65.07% (Q2 2025).